hrvatski jezikClear Cookie - decide language by browser settings

New Approaches for the Treatment of Chronic Graft-Versus-Host Disease: Current Status and Future Directions

Bennett Saidu, Nathaniel Edward; Bonini, Chiara; Dickinson, Anne; Grce, Magdalena; Inngjerdingen, Marit; Koehl, Ulrike; Toubert, Antoine; Zeiser, Robert; Galimberti, Sara (2020) New Approaches for the Treatment of Chronic Graft-Versus-Host Disease: Current Status and Future Directions. Frontiers in Immunology, 11 . ISSN 1664-3224

[img]
Preview
PDF - Published Version - article
Available under License Creative Commons Attribution.

Download (1MB) | Preview

Abstract

Chronic graft-versus-host disease (cGvHD) is a severe complication of allogeneic hematopoietic stem cell transplantation that affects various organs leading to a reduced quality of life. The condition often requires enduring immunosuppressive therapy, which can also lead to the development of severe side effects. Several approaches including small molecule inhibitors, antibodies, cytokines, and cellular therapies are now being developed for the treatment of cGvHD, and some of these therapies have been or are currently tested in clinical trials. In this review, we discuss these emerging therapies with particular emphasis on tyrosine kinase inhibitors (TKIs). TKIs are a class of compounds that inhibits tyrosine kinases, thereby preventing the dissemination of growth signals and activation of key cellular proteins that are involved in cell growth and division. Because they have been shown to inhibit key kinases in both B cells and T cells that are involved in the pathophysiology of cGvHD, TKIs present new promising therapeutic approaches. Ibrutinib, a Bruton tyrosine kinase (Btk) inhibitor, has recently been approved by the Food and Drug Administration (FDA) in the United States for the treatment of adult patients with cGvHD after failure of first-line of systemic therapy. Also, Janus Associated Kinases (JAK1 and JAK2) inhibitors, such as itacitinib (JAK1) and ruxolitinib (JAK1 and 2), are promising in the treatment of cGvHD. Herein, we present the current status and future directions of the use of these new drugs with particular spotlight on their targeting of specific intracellular signal transduction cascades important for cGvHD, in order to shed some light on their possible mode of actions.

Item Type: Article
Uncontrolled Keywords: chronic graft-versus-host disease; tyrosine kinase inhibitors; immunotherapy; Janus kinase 1/2; hematopoietic stem cell transplantation
Subjects: BIOMEDICINE AND HEALTHCARE > Clinical Medical Sciences
Divisions: Division of Molecular Medicine
Depositing User: Kristina Ciglar
Date Deposited: 06 Nov 2020 12:25
Last Modified: 06 Nov 2020 12:25
URI: http://fulir.irb.hr/id/eprint/5979
DOI: 10.3389/fimmu.2020.578314

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year

Contrast
Increase Font
Decrease Font
Dyslexic Font
Accessibility